Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: Results of the Japan Clinical Oncology Group Study 9104

Journal of Clinical Oncology

Volumn 20, Issue 14, 2002, Pages 3054-3060

  Takada, Minoru ^a   Fukuoka, Masahiro ^a   Kawahara, Masaaki ^a   Sugiura, Takahiko ^a   Yokoyama, Akira ^a   Yokota, Soichiro ^a   Nishiwaki, Yutaka ^a   Watanabe, Koshiro ^a   Noda, Kazumasa ^a   Tamura, Tomohide ^a   Fukuda, Haruhiko ^a   Saijo, Nagahiro ^a  

^a TONEYAMA NATIONAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESOPHAGITIS; FEMALE; FEVER; HUMAN; JAPAN; LEUKOPENIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RISK; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0037099617     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.12.071     Document Type: Article

References (24)

1. Small cell lung cancer: State-of-the-art therapy in 1996
2. A meta-analysis of thoracic radiotherapy for small-cell lung cancer
3. Accelerated hyperfractionated split course thoracic radiotherapy and infusion cisplatin based chemotherapy for small-cell lung cancer
4. Patients with limitedstage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine
5. Platinum combined with radiation therapy in small cell lung cancer: Focusing like a laser beam on crucial issues
6. Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation
7. Nonparametric estimation from incomplete observations
8. Conservatism of the approximation S(O-E)2/E in the log-rank test for survival data or tumour incidence data
9. Regression models and life table
10. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide
11. Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer: A prospective, randomized trial
12. Adriamycin and enhanced radiation reaction in normal esophagus and skin
13. Randomized trial of radiotherapy to the thorax in limited small-cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: A preliminary report
14. Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: A Southwest Oncology Group study
15. A preliminary report: Concurrent twice-daily radiotherapy plus platinum-etoposide chemotherapy for limited small cell lung cancer
16. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer
17. Concurrent cisplatinetoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer
18. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: A randomized study
19. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer: The National Cancer Institute of Canada Clinical Trials Group
20. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung
21. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer: Aarhus Lung Cancer Group